Articles

Partner pay up at local law firms

Partners at Indianapolis’ three largest law firms—Barnes & Thornburg LLP, Baker & Daniels LLP and Ice Miller LLP—are enjoying healthy pay increases despite the tough economic times.

Read More

Indiana AG won’t appeal immigration ruling

Indiana Attorney General Greg Zoeller says he won't appeal a federal judge's decision to temporarily block part of a new state immigration law but will continue to fight against a ruling that would make the ban permanent.

Read More

Golf course manager suing DuPont over herbicide

R.N. Thompson, which operates several local courses, claims the company’s Imprelis herbicide caused “catastrophic tree loss.” R.N. Thompson has joined a Pennsylvania resident in filing the class-action suit.

Read More

Prosecutor drops charges against OmniSource

Former Marion County Prosecutor Carl Brizzi brought stolen property charges against scrap yard operator OmniSource. But his successor, Terry Curry, said the evidence doesn’t support the allegations.

Read More

Lenders battling Broadbent legal strategy

Developer George P. Broadbent sold The Broadbent Co. to his wife for $50,000 in March 2010 as he faced a barrage of lawsuits threatening his control over the real estate company he co-founded in 1972. He has also transferred several properties to her.

Read More

Lilly asks judge to reject U.K. Zyprexa case

Eli Lilly and Co., the Indianapolis-based drugmaker whose best-selling schizophrenia medicine Zyprexa survived a patent challenge in Britain two years ago, has asked a United Kingdom judge to reject a parallel lawsuit by a generic drug company.

Read More

Who’s Who in Law – 2011

In a monthly feature that runs in the first issue of the month, through October, IBJ is identifying influential players in eight different industry categories. This month, our list draws from among the city’s finest legal minds in education, public-sector law, the judicial system and the broad swath of attorneys practicing solo and in firms of all sizes.

Read More

Zyprexa appeal rejected by Supreme Court

The U.S. Supreme Court has refused to revive a bid to press a $6.8 billion class-action suit against Eli Lilly and Co. over the marketing of Zyprexa, the company’s schizophrenia treatment.

Read More